The transcription factor Wilms' tumour gene 1 (WT1) is important as a prognostic marker as well as in the detection and monitoring of minimal residual disease in leukaemia and myelodysplastic syndromes. Evidence has accumulated over the past decade to show that WT1 is a key molecule for tumour proliferation in a large number of human neoplasms most prominent in acute leukaemias, making it a suitable target for therapeutic strategies. Based on animal results, showing safety and efficacy of immunization with WT1 peptides and protein, early clinical trials in leukaemia have recently been initiated.
Introduction
It was 15 years ago that in a series of papers published by the group of Housman in Cell, a polypeptide in the Wilms' tumour locus was identified as a tumour suppressor gene, which is inactivated in Wilms' tumour, a paediatric kidney cancer. [1] [2] [3] This polypeptide, displaying characteristic features of a transcription factor, and an expression restricted to kidney and haematopoetic cells, was called Wilms' tumour gene. In 1992, Miwa et al 4 first described expression of Wilms' tumour gene 1 (WT1) in a series of AML, ALL and CML samples, and supposed the involvement of this gene in the early stage of haematological cell differentiation. Inoue et al 5 reported, in 1994, the utility of WT1 as a new prognostic factor and MRD marker in acute leukaemia. Algar et al 6 could show that WT1 antisense oligonucleotides can inhibit proliferation and induce apoptosis in myeloid leukaemia cell lines. Since then, a considerable body of data has accumulated showing that WT1 is expressed in a wide range of haematopoietic and solid malignancies and is a key molecule for tumour cell proliferation. More recently, the demonstration that WT1-specific T cells can be generated in humans, which lyse leukaemic cells but spare normal haematopoetic progenitors, illustrated the potential of WT1 to serve as a target for immunotherapy. [7] [8] [9] The First International Conference on WT1 in Human Neoplasia was held in Berlin in March 2004 and brought together 96 clinicians and basic scientists from around the world who are engaged in research on WT1 to discuss and further elucidate the role of this transcription factor for tumour promotion and as a diagnostic and therapeutic target. This review covers the most recent aspects of WT1 research and summarizes the highlights of the presentations, and discussions held during this meeting.
Physiology and pathophysiology of WT1
WT1 was identified as a gene that plays an important role in normal kidney development and inactivation of its function was shown to result in the development of Wilms' tumours in paediatric patients. 10 Several lines of evidence indicate that WT1 is also involved in haematopoesis and the development of various other tissues, and disruption of WT1 function has been implicated in the formation of many different tumour types. Aberrant expression may be one mechanism by which the normal function of WT1 is disrupted. Using quantitative realtime PCR and immunohistochemistry, Yusuke Oji, Osaka, presented data that WT1 is not only highly expressed in leukaemia but also in a variety of nonhaematopoetic malignancies including lung cancer, colon cancer and pancreatic carcinomas. 11, 12 Interestingly, immunohistochemistry showed that the WT1 protein was sometimes aberrantly present in the cytosol instead of the nucleus. In accordance with leukaemia, in which mutations of the WT1 gene are infrequent, no WT1 mutations in 98 different cancer samples of nonhaematopoietic origin were found. Similar to leukaemia, WT1 antisense reduced WT1 protein levels and inhibited the growth of several WT1-expressing cancer cell lines. These data provide new insights into the central role of WT1 in tumorigenesis in a wide range of haematological and solid neoplasms.
The basis for abnormal overexpression of WT1 has not yet been fully elucidated. Mutations of the coding region of the wt1 gene occur in only 10-15% of AML.
13 WT1 expression may be upregulated by other transcription factors. Paired box genes PAX2, 14 PAX8, 15 and globin transcription factor 1 (GATA) 16 are the known physiological regulators of WT1. To gain an insight into the potential role of these transcription factors for the abnormal WT1 expression in tumours, Jan Siehl and Emilian Snarski, Berlin, studied levels of PAX2, PAX8 and GATA1 in AML and human carcinoma tissues. Using real-time quantitative RT-PCR analysis, PAX2 and PAX8 expression could be detected in 25 and 5% of AML samples (n ¼ 43), respectively, and expression levels of PAX2 and PAX8 both correlated with WT1 expression levels. 17 In breast and colorectal cancer cell lines PAX2 and PAX8 expression was observed more frequently (88 and 75% in eight breast cancer lines, and 67 and 73% in 15 colon cancer lines, respectively). Furthermore, high WT1 expression levels correlated with PAX2 and PAX8 expression in both cancer entities. These data provide evidence that PAX2 and PAX8 are potential candidate regulators of WT1 expression. In contrast to breast and colorectal cancer, other yet to be defined regulators for WT1 expression may play a more important role in leukaemia than PAX2 and PAX8. As a result of alternative splicing, alternative translational initiation sites and RNA editing, the WT1 gene can encode for as many as 24 different proteins. 18 These isoforms have been implicated in various cellular processes inducing proliferation, differentiation and apoptosis. WT1 acts as a transcription factor and so far more than 45 different target genes have been identified. In addition, WT1 may function as a transcriptional cofactor, and has also been implicated in post-transcriptional regulation, like RNA-splicing. To further study the biologic function of different WT1 isoforms Emelie Svensson and Urban Gullberg, Lund, studied the functional consequences of expression of WT1 splice variants and WT1 mutants in primary human haematopoietic CD34 þ cells. Ectopic expression of a common splice variant of WT1 lacking the KTS-insert in the zinc-finger domain inhibited the formation of erythroid colonies, whereas expression of a WT1-mutant lacking the entire zinc finger region, which cannot bind DNA, had no effect. In the same experiment, ectopic expression of WT1 lacking the KTS-insert reduced myeloid clonogenic growth and stimulated myeloid differentiation. Interestingly, expression of the WT1-mutant resulted in the same phenotype. These data demonstrate that WT1 can affect proliferation and differentiation of myeloid and erythroid cells by different molecular mechanisms. Aswin Menke and Joop Jansen, Njimegen, investigated the biological activities of the four major WT1-isoforms and two of the most commonly found mutations in leukaemia. Colony assays using retrovirally transduced primary murine bone marrow (BM) cells showed that all four isoforms inhibited colony formation, albeit with different potential. In contrast to the findings by Dr Svensson, expression of the WT1 mutant forms had no effect on the colony forming potential. This difference might be explained by the cell type-dependent effects of WT1, which have been described in literature.
WT1 as diagnostic tool
Overexpression of WT1 in leukaemic blasts of AML and ALL patients, and in myelodysplastic syndromes (MDS), is well documented both on RNA and protein levels. 4, 19, 20 Physiologic haematopoietic stem cell compartments also express WT1. 21 However, there is an agreement that a 'malignant' WT1 expression can be clearly distinguished from a physiologic expression based on quantitative detection methods such as semiquantitative RT-PCR, and real-time quantitative RT-PCR (qRT-PCR). Uncertainty remains, however, whether monitoring WT1 expression in acute leukaemia and MDS patients is accurate enough to guide therapeutic decisions.
Joop Janssen, Nijmegen, presented interesting data on the expression of WT1 in subsets of haematopoietic progenitors from AML and MDS patients extending his previous studies. 22 A significantly higher WT1 expression (3-100-fold) was found in total BM mononuclear cells (MNC) from MDS patients than in healthy BM controls. The highest WT1 expression was detected in primitive CD34 þ rhodamine-123 dull cells from healthy donors, AML and MDS patients. Contrary to normal CD34-negative haematopoietic progenitors, he also found WT1 expression in CD34-negative AML or MDS blasts. Subfraction analysis of BM cells was performed in three MDS patients and WT1 expression was completely restricted to the erythroid cells in one patient, whereas WT1 expression was found in the nonerythroid compartment in another patient. Janssen concluded that the abnormal WT1 expression is a useful molecular marker for AML and MDS, which may contribute to the disturbed differentiation of haematopoietic cells in MDS patients.
Using qRT-PCR, various authors were able to show the usefulness of WT1 expression as a marker for minimal residual disease (MRD) in acute leukaemia patients. [23] [24] [25] [26] Daniela Cilloni, Turin, confirmed and extended these earlier findings showing that measuring WT1 transcripts is very useful for MRD detection in AML and ALL patients. Interestingly, WT1 transcript numbers paralleled other molecular markers used for MRD monitoring. Increased WT1 expression (above normal range) always indicated impending haematological relapse, even in patients lacking other molecular disease markers. Contrarily, normal WT1 copy numbers in treated acute leukaemia patients were always associated with persisting complete remission. She also presented detailed data for the prognostic role of WT1 in MDS. In most MDS patients, including refractory anaemia, WT1 was expressed in both peripheral blood and BM above the range observed in normal controls. A good correlation of the WT1 expression levels with the clinical subsets (WHO classification) and the IPSS (International Prognostic Scoring System), a frequently used risk assessment system for MDS could be shown. 27 Using qRT-PCR it was even possible to define a cut-off level of 1000 WT1 copies per 10 4 ABL copies to distinguish between the intermediate-low risk and the intermediate-high risk subgroups of MDS. This distinction is of high-clinical relevance regarding therapeutic decisions, since it determines if a particular MDS patient is to receive more aggressive chemotherapy. By extending the results of Tamaki et al, 28 she also showed that longitudinal monitoring of WT1 expression levels can be used as a marker for MDS disease progression. Recently, various studies have also analysed the usefulness of WT1 for disease monitoring in paediatric acute leukaemia. [29] [30] [31] Morris Kletzel, Chicago, prospectively analysed WT1 levels in children diagnosed with AML or ALL at presentation, relapse, or in sustained remission using semi-quantitative RT-PCR. In his large series of 204 samples, 95 and 100% of ALL and AML samples, respectively, showed high-level WT1 expression, both, at presentation and relapse. 29 Contrarily, only five of 90 samples obtained in remission showed significantly increased WT1 expression. These five patients relapsed within the next 2-6 months. In another series of paediatric AML patients, Jan Trka, Prague, reported a significant correlation between very low WT1 expression at presentation determined by qRT-PCR and a favourite clinical outcome after therapy. 30 In monitoring MRD, they found for 28 AML patients an excellent correlation between WT1 transcript levels, leukaemic disease monitoring by threecolour flow cytometry, and the clinical course of disease. Takako Miyamura, Osaka, presented RT-PCR data on MRD in 31 paediatric AML patients. Children with increased WT1 and/ or leukaemia-specific fusion gene expression after the first consolidation therapy (presence of MRD) were recommended to undergo stem cell transplantation (SCT). On presentation, only 58.1% (18 of 31) of the AML patients were positive for WT1 expression (more than 10 3 WT1 copies/mg RNA). 31 After the first consolidation therapy, WT1 expression became negative in 14 of 18 patients. Four children with persistently high WT1 expression after first consolidation underwent SCT, but only one child remained in complete remission. Of 6 copies/mg RNA) were found to have a grim prognosis even after SCT at the first complete remission.
The presented data were thoroughly discussed by authors and audience and it was concluded that measuring WT1 expression in adult and paediatric AML, MDS, and ALL patients is of great value for disease management. However, standardization of the various PCR protocols (from blood sampling to cDNA amplification) is needed to create a robust basis for therapeutic decisions relating to the management of acute leukaemia patients. Further, prospective studies are necessary to analyse WT1 expression at defined time points of leukaemia therapy protocols. Such studies should definitely answer the question of whether monitoring of WT1 expression will ultimately result in superior treatment decisions for acute leukaemia patients.
WT1 as target for immunotherapy
There is growing evidence that WT1 is a highly interesting antigen to target in immunotherapy of cancer. WT1 shows high expression in a wide range of malignant neoplasms, is absent or shows very low expression in normal tissues and plays a key role in tumour cell proliferation. Studies in mice revealed that T-cell responses against WT1 could readily be elicited, and were associated with tumour control. [32] [33] [34] In vitro and murine models Hans Stauss, London, discussed the potential interference of tolerance mechanisms for the generation of high avidity cytotoxic T cell (CTL) responses against tumour cells expressing tumour-associated antigens such as WT1. Although tumour antigens are often expressed at elevated levels in tumour cells, they are also expressed in normal tissues, which may trigger tolerance of high avidity CTL. Two approaches to circumvent CTL tolerance were presented by Stauss. Tolerance to HLA-A2-presented epitopes of WT1 was circumvented by in vitro isolation of HLA-A2-restricted CTL from HLA-A2-negative healthy donors. 7 Tolerance to HLA-A2-presented epitopes of human MDM2 and p53 was circumvented by isolating HLA-A2-restricted CTL from HLA-A2 transgenic mice. 35 The HLA-A2-restricted human and murine CTL were shown to specifically kill human tumour cells expressing WT1 and MDM2/p53, respectively. Adoptive transfer of high-avidity MDM2-specific CTL significantly prolonged survival of tumour bearing H2 dxb F1 mice. CTL did not attack normal tissues. In tumour bearing mice Stauss could show, however, that CTL were rendered tolerant in vivo. 36 Mathias Theobald, Mainz, demonstrated that the retroviral transfer of T-cell receptors isolated from WT1-specific human CTL and from MDM2-or p53-specific murine CTL was an attractive strategy to confer antigen-specificity to polyclonally activated human T-cell populations. 37 Several groups have already shown that immunization of mice with WT1 peptide or WT1 cDNA can induce WT1-specific CTLs and the resultant rejection of challenges by WT1-expressing tumour cells, [32] [33] [34] indicating that WT1 can serve as a tumour rejection antigen. Two groups in this session showed novel experimental in vivo systems, in which the potential of WT1 as a tumour rejection antigen can be evaluated more precisely. HLA-An2402 is one of the common HLA class I types, and the most common in the Japanese population. Masaki Yasukawa, Ehime, presented in vitro studies using two HLAAn2402-restricted, WT1-specific CD8 þ CTL clones, TAK-1 and NIM-1, which were generated by stimulating CD8 þ T cells with WT1 peptide WT1 235-243 and WT1 417-425, respectively. TAK-1 and NIM-1 were cytotoxic to HLA-An2402-positive leukaemia cells, but not to normal cells. 8 Adoptive transfer of WT1-specific CTLs into nude mice that had been engrafted with an HLA-An2402-positive lung cancer cell line resulted in inhibition of the cancer cell growth and prolonged survival of the mice. 38 These findings indicate that WT1-specific CTLs can also lyse solid tumour cells in vivo. Hiroko Nakajima, Osaka, presented results from a therapeutic model using murine tumour and mouse-type WT1 peptide. 39 An intradermal injection of Mycobacterium bovis bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) into mice, followed by that of WT1 peptide at the same site on the next day, generated WT1-specific CTLs and led to the rejection of WT1-expressing leukaemia or lung cancer cells, which had been transplanted into the mice. Furthermore, no damage to normal tissues was observed in the mice. WT1 peptide vaccination combined with BCG-CWS may therefore be developed as cancer immunotherapy in clinical settings.
Yasukawa further showed that myeloma cells, whose WT1 expression levels were not as high as those in leukaemia cells, could also be lysed by WT1-specific CTLs, because myeloma cells had high sensitivity to perforin produced by CTLs. 40 This new finding suggests that multiple myeloma may also be sensitive to WT1-based immunotherapy.
Spontaneous immune responses to WT1 and vaccine development
There is now ample evidence that WT1 is immunogenic in patients with WT1-overexpressing tumours as spontaneous development of both specific antibodies and T cells could be shown in several studies. [41] [42] [43] Olga Elisseeva, Osaka, presented data on a detailed analysis of WT1 antibody isotypes in patients with haematological malignancies. In leukaemias and MDS, T helper (Th) 1-type WT1 antibodies such as IgG1, IgG2 and IgG3 were significantly increased in both detection rate and antibody titers compared to those in healthy volunteers, whereas Th2-type WT1 antibodies such as IgG4 did not increase. 44 Immunoglobulin isotype class switch from IgM to IgG occurs in patients with MDS along with disease progression towards leukaemia. The presence of IgG type of WT1 antibodies in the sera of patients with leukaemia and advanced stages of MDS suggests that induction of Th response against WT1, which is needed for class switch, may occur with increase in tumour burden. Lutz Uharek, Berlin, had analysed T-cell responses to WT1 and other leukaemia-associated antigens in patients following allogeneic stem cell transplantion. He presented ELISPOT assay data from patients with acute and chronic myeloid leukaemia, showing that during the first 6-12 weeks following allotransplantion many patients mount considerable, albeit transient WT1-specific T cell responses. He concluded that WT1 might also be a promising antigen to target by vaccination following allogeneic transplantion.
Clinical studies of WT1 vaccination are limited so far to patients with HLA-A2 and HLA-A24 haplotypes as neither epitopes for other HLA class I alleles nor class II alleles have been identified to date. Anne Marie Asemissen, Berlin, presented a new approach to identify immunogenic epitopes from WT1. Five candidate epitopes in the sequence of WT1 with HLA-An01-binding motifs were identified by a MHC-binding prediction algorithm. One of these five peptides showed a highly spontaneous immunogenicity as two of four patients with AML and three of 10 allogeneic stem cell recipients displayed between 0.4 and 1.5% CD8 þ T cells reactive with this peptide in peripheral blood. Proteasomal degradation assays further demonstrated natural processing of this WT1 peptide. The strong immunogenicity makes this epitope particularly interesting for use in vaccination and for the analysis of spontaneous T cell responses. Javier Pinilla-Ibarz, New York, presented data on an approach to generate more immunogenic peptide analogues. His group has generated WT1 analogue peptides with improved binding to and stabilization of HLA class I. He showed that these peptides can produce larger immune responses in vitro than the native peptide. T cells stimulated with the analogues crossreact with the native peptides. Further, T cells stimulated with the analogues can recognize and kill CML blasts. Alexander Gaiger, Vienna and Martin Cheever, Seattle, have preclinically developed a WT1 protein subunit vaccine preparation. Gaiger presented data from murine models showing that the truncated protein is markedly more immunogenic than the whole WT1 protein and induces strong CD4 þ T-cell and antibody responses and occasional CD8 þ T-cell responses. Cheever showed data on the development of a microsphere formulation encapsulating WT1 protein in a biodegradable polymer. The WT1 microsphere can be readily phagocytosed by antigenpresenting cells and processed via MHC class I and II molecules, generating strong CD4 þ , CD8 þ T cell and antibody responses. Human vaccine trials in leukaemia are planned with WT1 protein/microspheres, exploiting the advantage of broad HLA coverage.
Results from first clinical vaccination studies
For several years, WT1 has been proposed as a candidate antigen for tumour-directed immunotherapy 45 and clinical vaccination trials have recently been initiated in Japan and Germany. Carmen Scheibenbogen, Berlin, reported results on the first four AML patients treated within an ongoing phase I/II WT1 peptide vaccination study. HLA-A2-positive patients receive repeated WT1 126-134 peptide i.d./s.c. injections at a dose of 0.2 mg, in combination with GM-CSF and keyhole limpet haemocyanin as T-helper adjuvant. Induction of WT1-specific T-cell responses was detected in three of four patients with up to 0.92, 0.43, and 0.42% in peripheral blood and up to 0.8% CD3 þ CD8 þ T cells in BM by tetramer analysis and intracellular cytokine cytometry. The first patient, who had a second partial remission at study onset and progressed during the initial 4 weeks of vaccination with an increase of marrow blasts to 30%, subsequently achieved a complete remission (CR) after six vaccinations. 46 The second patient, who had a formal CR following chemotherapy for secondary AML with persistance of residual marrow blasts and a highly unfavourable 11q23 abnormality has been in continuous CR for more than 2 years since initiation of vaccination. Patients 3 and 4 had high numbers of marrow blasts when vaccination was started. While patient 4 rapidly progressed after 4 vaccinations, a transient disease stabilization with a decrease of the elevated LDH could be achieved in patient 3. In accordance with the clinical course, in patients 1 and 2 normalization of elevated WT1 transcripts was observed following vaccination. No side effects were noted beyond those typically seen with GM-CSF.
Clinical and immunological results were also presented from the first clinical trial of WT1-A24-peptide-based vaccination in patients with acute leukaemia, MDS, and lung cancer conducted at the Osaka University Clinic. Patients were intradermally injected with increasing doses of 0.3, 1, or 3 mg of an HLA-An2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. 47 Yoshihiro Oka showed results from two MDS patients, in whom clinical responses were observed. In a patient with overt leukaemia from MDS, only a single dose of WT1 vaccination induced an increase in WT1-specific CTLs and a resultant rapid reduction in WT1 level and leukaemic blast cells. Profound reduction in leukocytes was also observed. 48 A similar phenomenon was observed in a patient with MDS with myelofibrosis. Akihiro Tsuboi presented clinical data from two patients with lung cancer who received WT1 vaccination. A reduction in tumour markers CEA and SLX and/or a transient decrease in tumour size were observed. 49 No adverse effects except local erythema at the WT1 vaccine injection sites were noted upon repeated vaccinations. Treatment with WT1 vaccination for other patients including, de novo acute leukaemia and breast cancer, are currently ongoing at the Osaka University Clinic. Immunological results from the first 12 AML patients, who had been vaccinated in CR following chemotherapy showed induction of WT1-specific T cells in eight of 12 patients. In four patients, vaccination resulted in a decrease of WT1 levels, which had still been enhanced at study onset following chemotherapy. 50 Taken together, the findings from early clinical trials are very promising and show the efficacy of peptide-based vaccines to induce WT1-specific T cells associated with clinical efficacy.
Summary and perspectives
The 2-day Berlin conference was an exciting starting point for gathering and exchanging comprehensive information on WT1 as a key tumour-promoting molecule and likewise as a versatile target for a variety of immunological treatment strategies. Crucial areas for future research have been identified, including elucidation of the underlying mechanisms resulting in overexpression of WT1 in a variety of haematopoietic neoplasms and carcinomas, identification of modes to control the detrimental overexpression, and development of clinically effective immunological treatment strategies. Important initial steps have been made in all three areas, which should direct and encourage further research efforts. One point requiring clarification is the cellular localization of WT1, as nuclear dominance has been observed in several neoplasms, and cytosolic presence in others. It is unclear, whether there is also a cytosolic function of the transcription factor WT1, and conversely the efficacy of presentation of WT1-derived peptides to T cells via MHC class I molecules is unclear, in case WT1 is located in the nucleus. Of special interest for clinicians are the findings of WT1 detection as a marker for MRD in AML and as a prognostic factor in MDS, and also the initial success of vaccination with WT1 in patients with AML and lung cancer. Further clinical studies are urgently needed and under way to confirm and extend these initial results. In order to maintain the broad dialogue, it is planned to hold further conferences, concentrating on the most novel aspects of WT1 research, with the next meeting scheduled to take place in Osaka, Japan, October 20-22, 2005. 
